

Select High Cost, Orphan, and Accelerated Approval Drugs

This data table provides interim coverage information for a list of select drugs, including high cost drugs, orphan drugs, and other drugs approved under a Food and Drug Administration (FDA) accelerated approval pathway. These drugs are covered for FDA-approved indications when medically necessary. Information about a drug's FDA-approved indication(s) can be found on the FDA website. Specific interim billing and coverage information for each drug can be found in the table below. These drugs and the billing or coverage of ancillary services related to these drugs are subject to all existing ForwardHealth coverage and billing policy, which may be found in the [ForwardHealth Online Handbook](#) on the ForwardHealth Portal.

If a drug listed below has established drug-specific clinical criteria, refer to the [Services Requiring Prior Authorization](#) chapter of the Prior Authorization section of the Pharmacy service area of the Online Handbook on the Portal for information about the clinical criteria and directions for submitting prior authorization (PA) requests.

If a drug listed below requires PA to support that use is for an FDA-approved indication and is medically necessary as defined by Wis. Admin. Code § DHS 101.03(96m) but does not have drug-specific clinical criteria, PA requests must be submitted using Section VII (Clinical Information for Other Drug Requests) of the Prior Authorization/Drug Attachment (PA/DGA) form, F-11049 (01/2024), and the Prior Authorization Request Form (PA/RF), F11018 (04/2026). Medical records (e.g., chart notes, laboratory values) must be submitted along with the PA request to support that use is both medically necessary and for an FDA-approved indication. The drug must be prescribed in a dose and manner consistent with FDA-approved product labeling.

For specific questions about the billing or coverage of high cost, orphan, and accelerated approval drugs listed in this data table, providers may contact Provider Services at 800-9479627 or email DHSOrphanDrugs@dhs.wisconsin.gov.

Note: The information contained in this data table is subject to change, and it is the provider's responsibility to remain up-to-date with the information included in this data table.

Effective: 11/01/2026

ABECMA idecabtagene	<ul style="list-style-type: none">○ Abecma does not require PA.○ Abecma will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines).○ Abecma will be covered under the pharmacy benefit.○ To bill ForwardHealth for Abecma, pharmacy providers should submit a pharmacy noncompound drug claim.
AMONDYS 45 casimersen	<ul style="list-style-type: none">○ Amondys 45 requires PA to support that use is for an FDA-approved indication and is medically necessary.○ If a PA request for Amondys 45 is approved, Amondys 45 will be covered under the pharmacy benefit.○ To bill ForwardHealth for Amondys 45, pharmacy providers should submit a pharmacy noncompound drug claim.

AUCATZYL obecabtagene autoleucel	<ul style="list-style-type: none"> ○ Aucatzyl does not require PA. ○ Aucatzyl will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Aucatzyl will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Aucatzyl pharmacy providers should submit a pharmacy noncompound drug claim.
AVLAYAH tividenufusp alfa-eknm	<ul style="list-style-type: none"> ○ Avlayah requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Avlayah is approved, Avlayah will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Avlayah, pharmacy providers should submit a pharmacy noncompound drug claim.
BREYANZI lisocabtagene maraleucel	<ul style="list-style-type: none"> ○ Breyanzi does not require PA. ○ Breyanzi will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Breyanzi will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Breyanzi, pharmacy providers should submit a pharmacy noncompound drug claim.
BRINEURA cerliponase	<ul style="list-style-type: none"> ○ Brineura does not require PA. ○ Brineura will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Brineura will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Brineura, pharmacy providers should submit a pharmacy noncompound drug claim.
CARVYKTI ciltacabtagene	<ul style="list-style-type: none"> ○ Carvykti does not require PA. ○ Carvykti will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Carvykti will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Carvykti, pharmacy providers should submit a pharmacy noncompound drug claim.
CASGEVY exagamglogene autotemcel	<ul style="list-style-type: none"> ○ Casgevy requires PA; established clinical criteria for Casgevy can be found in the Online Handbook on the Portal. ○ If a PA request for Casgevy is approved, Casgevy will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Casgevy, pharmacy providers should submit a pharmacy noncompound drug claim.

CEREZYME imiglucerase	<ul style="list-style-type: none"> ○ Cerezyme does not require PA. ○ Cerezyme will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Cerezyme will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Cerezyme, pharmacy providers should submit a pharmacy noncompound drug claim.
CRYSVITA burosumab-twza	<ul style="list-style-type: none"> ○ Crysvita requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Crysvita is approved, Crysvita will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Crysvita, pharmacy providers should submit a pharmacy noncompound drug claim.
ELAPRASE idursulfase	<ul style="list-style-type: none"> ○ Elaprase does not require PA. ○ Elaprase will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Elaprase will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Elaprase, pharmacy providers should submit a pharmacy noncompound drug claim.
ELEVIDYS delandistrogene moxeparvovec-rokl	<ul style="list-style-type: none"> ○ Elevidys requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Elevidys is approved, Elevidys will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Elevidys, pharmacy providers should submit a pharmacy noncompound drug claim.
ENCELTO revakinagene taroretcel-lwey	<ul style="list-style-type: none"> ○ Encelto requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Encelto is approved, Encelto will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Encelto, pharmacy providers should submit a pharmacy noncompound drug claim.
EXONDYS 51 eteplirsen	<ul style="list-style-type: none"> ○ Exondys 51 requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Exondys 51 is approved, Exondys 51 will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Exondys 51, pharmacy providers should submit a pharmacy noncompound drug claim.
FAYUVI rebisufligene etisparvovec-hopf	<ul style="list-style-type: none"> ○ Fayuvi requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Fayuvi is approved, Fayuvi will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Fayuvi, pharmacy providers should submit a pharmacy noncompound drug claim.

<p>GAMIFANT emapalumab-lzsg</p>	<ul style="list-style-type: none"> ○ Gamifant requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Gamifant is approved, Gamifant will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Gamifant, pharmacy providers should submit a pharmacy noncompound drug claim.
<p>GENGLYCOS pariglasgene brecaparvovec-opnr</p>	<ul style="list-style-type: none"> ○ Genglycos requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ The prescriber will be contacted by ForwardHealth for a peer-to-peer review to validate medical necessity. ○ If a PA request for Genglycos is approved, Genglycos will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Genglycos, pharmacy providers should submit a pharmacy noncompound drug claim.
<p>HEMGENIX etranacogene dezaparvovec - drlb</p>	<ul style="list-style-type: none"> ○ Hemgenix requires PA; established clinical criteria for Hemgenix can be found in the Online Handbook on the Portal. ○ The provider will be contacted by ForwardHealth for a peer-to-peer review to validate the medical necessity. ○ If a PA request for Hemgenix is approved, Hemgenix will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Hemgenix, pharmacy providers should submit a pharmacy noncompound drug claim.
<p>ISEMBYLD apitegromab-mstn</p>	<ul style="list-style-type: none"> ○ Isembyld requires PA. ○ A PA/DGA form Section VII must be submitted with the following clinical documentation and medical records to support the member's medical condition and outline the member's current treatment plan. <ul style="list-style-type: none"> • The member is 2– 21 years of age • The member has spinal muscular atrophy (SMA) type 2, or 3 confirmed by genetic testing (5q SMN1 homozygous mutation, homozygous gene deletion, or compound heterozygous mutation) • The member is currently receiving an SMN2 targeted treatment and has received one of the following: <ul style="list-style-type: none"> ▪ Spinraza, for at least 10 months of dosing before screening ▪ Evrysdi, for at least 6 months of dosing before screening • The member has a baseline Hammersmith Functional Motor Scale Expanded (HFMSE) score greater than or equal to 10 and less than and equal to 45 at screening • The provider submits the member's current pulmonary status, including any requirement for ventilator support ○ ForwardHealth will consider coverage for Isembyld on a case-by-case basis if any of the following circumstances are present: <ul style="list-style-type: none"> • Complete paralysis of the limbs

	<ul style="list-style-type: none"> • Ventilator dependent for 16 or more hours per day, including non-invasive respiratory support <ul style="list-style-type: none"> ○ A copy of the member's medical records must be submitted and sufficiently document: <ul style="list-style-type: none"> • Information listed in the clinical criteria for PA approval • Current and previous SMA therapies • Baseline motor function status • Member's current treatment plan ○ ForwardHealth will deny PA requests for Isembyld if any of the following circumstances are present: <ul style="list-style-type: none"> • The member is currently involved in a clinical trial for an SMA drug. • The member is diagnosed with a non-SMN1 variant of SMA. • The member is not currently receiving an SMN2 treatment. • The member has been previously treated with Zolgensma or Itvisma. ○ If a PA request for Isembyld is approved, Isembyld will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Isembyld, pharmacy providers should submit a pharmacy noncompound drug claim.
ITVISMA onasemnogene abeparvovec-brve	<ul style="list-style-type: none"> ○ Itvisma requires PA; established clinical criteria for Itvisma can be found in the Online Handbook on the Portal. ○ If a PA request for Itvisma is approved, Itvisma will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Itvisma, pharmacy providers should submit a pharmacy noncompound drug claim.
KRESLADI marnetegrane autotemcel	<ul style="list-style-type: none"> ○ Kresladi requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Kresladi is approved, Kresladi will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Kresladi, pharmacy providers should submit a pharmacy noncompound drug claim.
KYMRIAH tisagenlecleucel	<ul style="list-style-type: none"> ○ Kymriah does not require PA. ○ Kymriah will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Kymriah will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Kymriah, pharmacy providers should submit a pharmacy noncompound drug claim.
LENMELDY atidarsagene autotemcel	<ul style="list-style-type: none"> ○ Lenmeldy requires PA; established clinical criteria for Lenmeldy can be found in the Online Handbook on the Portal. ○ If a PA request for Lenmeldy is approved, Lenmeldy will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Lenmeldy, pharmacy providers should submit a pharmacy noncompound drug claim.

LUXTURNA voretigene neparvovecrzyl	<ul style="list-style-type: none"> ○ Luxturna requires PA; established clinical criteria for Luxturna can be found in the Online Handbook on the Portal. ○ If a PA request for Luxturna is approved, Luxturna will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Luxturna, pharmacy providers should submit a pharmacy noncompound drug claim.
LYFGENIA lovotibeglogene autotemcel	<ul style="list-style-type: none"> ○ Lyfgenia requires PA; established clinical criteria for Lyfgenia can be found in the Online Handbook on the Portal. ○ If a PA request for Lyfgenia is approved, Lyfgenia will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Lyfgenia, pharmacy providers should submit a pharmacy noncompound drug claim.
MEPSEVII vestronidase alfa-vjbjk	<ul style="list-style-type: none"> ○ Mepsevii requires PA to support that use is for an FDA approved indication and is medically necessary. ○ If a PA request for Mepsevii is approved, Mepsevii will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Mepsevii, pharmacy providers should submit a pharmacy noncompound drug claim.
ONPATTRO patisiran	<ul style="list-style-type: none"> ○ Onpattro does not require PA. ○ Onpattro will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Onpattro will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Onpattro, pharmacy providers should submit a pharmacy noncompound drug claim.
OXERVATE cenegermin	<ul style="list-style-type: none"> ○ Oxervate does not require PA. ○ Oxervate will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Oxervate will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Oxervate, pharmacy providers should submit a pharmacy noncompound drug claim.
PAPZIMEOS zopapogene imadenovec-drba	<ul style="list-style-type: none"> ○ Papzimeos requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Papzimeos is approved, Papzimeos will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Papzimeos, pharmacy providers should submit a pharmacy noncompound drug claim.

RUZURGI amifampridine	<ul style="list-style-type: none"> ○ Ruzurgi requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Ruzurgi is approved, Ruzurgi will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Ruzurgi, pharmacy providers should submit a pharmacy noncompound drug claim.
RYONCIL remestemcel-L-rknd	<ul style="list-style-type: none"> ○ Ryoncil does not require PA. ○ Ryoncil will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines). ○ Ryoncil will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Ryoncil, pharmacy providers should submit a pharmacy noncompound drug claim.
SKYSONA elivaldogene	<ul style="list-style-type: none"> ○ Skysona requires PA; established clinical criteria for Skysona can be found in the Online Handbook on the Portal. ○ If a PA request for Skysona is approved, Skysona will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Skysona, pharmacy providers should submit a pharmacy noncompound drug claim.
SPINRAZA nusinersen	<ul style="list-style-type: none"> ○ Spinraza requires PA; established clinical criteria for Spinraza can be found in the Online Handbook on the Portal. ○ If a PA request for Spinraza is approved, Spinraza will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Spinraza, pharmacy providers should submit a pharmacy noncompound drug claim.
TECARTUS brexucabtagene	<ul style="list-style-type: none"> ○ Tecartus does not require PA. ○ Tecartus will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Tecartus will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Tecartus, pharmacy providers should submit a pharmacy noncompound drug claim.
TECELRA afamitresgene	<ul style="list-style-type: none"> ○ Tecelra does not require PA. ○ Tecelra will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Tecelra will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Tecelra, pharmacy providers should submit a pharmacy noncompound drug claim

TREGZI allo reg tcell, hspc, tcell- vldq	<ul style="list-style-type: none"> ○ Tregzi requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Tregzi is approved, Tregzi will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Tregzi, pharmacy providers should submit a pharmacy noncompound drug claim.
VILTEPSO viltolarsen	<ul style="list-style-type: none"> ○ Viltepso requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Viltepso is approved, Viltepso will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Viltepso, pharmacy providers should submit a pharmacy noncompound drug claim.
VIMIZIM elosulfase alfa	<ul style="list-style-type: none"> ○ Vimizim does not require PA. ○ Vimizim will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Vimizim will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Vimizim, pharmacy providers should submit a pharmacy noncompound drug claim.
VYJUVEK beremagene geperpavec-svdt	<ul style="list-style-type: none"> ○ Vyjuvek requires PA; established clinical criteria for Vyjuvek can be found in the Online Handbook on the Portal. ○ If a PA request for Vyjuvek is approved, Vyjuvek will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Vyjuvek, pharmacy providers should submit a pharmacy noncompound drug claim.
VYONDYS 53 golodirsen	<ul style="list-style-type: none"> ○ Vyondys 53 requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Vyondys 53 is approved, Vyondys 53 will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Vyondys 53, pharmacy providers should submit a pharmacy noncompound drug claim.
WASKYRA etuvetidigene autoemcel	<ul style="list-style-type: none"> ○ Waskyra requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Waskyra is approved, Waskyra will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Waskyra, pharmacy providers should submit a pharmacy noncompound drug claim.
YESCARTA axicabtagene ciloleucel	<ul style="list-style-type: none"> ○ Yescarta does not require PA. ○ Yescarta will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines). ○ Yescarta will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Yescarta, pharmacy providers should submit a pharmacy noncompound drug claim.

ZANVASTRO zilganersen	<ul style="list-style-type: none"> ○ Zenvastro requires PA to support that use is for an FDA-approved indication and is medically necessary. ○ If a PA request for Zenvastro is approved, Zenvastro will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Zenvastro, pharmacy providers should submit a pharmacy noncompound drug claim.
ZEVASKYN prademagene zamikeracel	<ul style="list-style-type: none"> ○ Zevaskyn requires PA to support that use is for an FDA approved indication and is medically necessary. ○ If a PA request for Zevaskyn is approved, Zevaskyn will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Zevaskyn, pharmacy providers should submit a pharmacy noncompound drug claim.
ZOLGENSMA onasemnogene abeparvovec-xioi	<ul style="list-style-type: none"> ○ Zolgensma requires PA; established clinical criteria for Zolgensma can be found in the Online Handbook on the Portal. ○ If a PA request for Zolgensma is approved, Zolgensma will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Zolgensma, pharmacy providers should submit a pharmacy noncompound drug claim.
ZYNTGLO betibeglogene	<ul style="list-style-type: none"> ○ Zynteglo requires PA; established clinical criteria for Zynteglo can be found in the Online Handbook on the Portal. ○ If a PA request for Zynteglo is approved, Zynteglo will be covered under the pharmacy benefit. ○ To bill ForwardHealth for Zynteglo, pharmacy providers should submit a pharmacy noncompound drug claim.

Note: Pharmacy providers who receive Medicaid reimbursement for select high cost, orphan, and accelerated approval drugs may be subject to audit at any time. Pharmacy providers are required to retain relevant documentation supporting adherence to ForwardHealth program requirements and produce it for and/or submit it to ForwardHealth upon request. ForwardHealth may deny or recoup payment for services that fail to meet program requirements.